Literature DB >> 28373263

Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.

Harold C Sullivan1, Christian Gerner-Smidt1, Ajay K Nooka2, Connie M Arthur1, Louisa Thompson1, Amanda Mener1, Seema R Patel1, Marianne Yee3, Ross M Fasano1, Cassandra D Josephson1, Richard M Kaufman4, John D Roback1, Sagar Lonial2, Sean R Stowell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28373263      PMCID： PMC5454337          DOI： 10.1182/blood-2016-11-749432

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   25.476


× No keyword cloud information.
  22 in total

1.  CD8+ T cells mediate antibody-independent platelet clearance in mice.

Authors:  Connie M Arthur; Seema R Patel; H Cliff Sullivan; Annie M Winkler; Chris A Tormey; Jeanne E Hendrickson; Sean R Stowell
Journal:  Blood       Date:  2016-01-19       Impact factor: 22.113

2.  Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

Authors:  Michel de Weers; Yu-Tzu Tai; Michael S van der Veer; Joost M Bakker; Tom Vink; Daniëlle C H Jacobs; Lukas A Oomen; Matthias Peipp; Thomas Valerius; Jerry W Slootstra; Tuna Mutis; Wim K Bleeker; Kenneth C Anderson; Henk M Lokhorst; Jan G J van de Winkel; Paul W H I Parren
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

3.  A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation.

Authors:  Kathryn R Girard-Pierce; Sean R Stowell; Nicole H Smith; C Maridith Arthur; Harold C Sullivan; Jeanne E Hendrickson; James C Zimring
Journal:  Blood       Date:  2013-07-22       Impact factor: 22.113

4.  Antigen modulation confers protection to red blood cells from antibody through Fcγ receptor ligation.

Authors:  Sean R Stowell; Justine S Liepkalns; Jeanne E Hendrickson; Kathryn R Girard-Pierce; Nicole H Smith; C Maridith Arthur; James C Zimring
Journal:  J Immunol       Date:  2013-10-09       Impact factor: 5.422

5.  Nonhemolytic antibody-induced loss of erythrocyte surface antigen.

Authors:  James C Zimring; Gregory A Hair; Traci E Chadwick; Seema S Deshpande; Kimberly M Anderson; Christopher D Hillyer; John D Roback
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

6.  Transient production of anti-LW by LW-positive people.

Authors:  B Chown; H Kaita; B Lowen; M Lewis
Journal:  Transfusion       Date:  1971 Jul-Aug       Impact factor: 3.157

7.  Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.

Authors:  Michael S van der Veer; Michel de Weers; Berris van Kessel; Joost M Bakker; Shulamiet Wittebol; Paul W H I Parren; Henk M Lokhorst; Tuna Mutis
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

8.  When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.

Authors:  Marlies Oostendorp; Jeroen J Lammerts van Bueren; Parul Doshi; Imran Khan; Tahamtan Ahmadi; Paul W H I Parren; Wouter W van Solinge; Karen M K De Vooght
Journal:  Transfusion       Date:  2015-05-18       Impact factor: 3.157

9.  Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.

Authors:  Christopher McCudden; Amy E Axel; Dominique Slaets; Thomas Dejoie; Pamela L Clemens; Sandy Frans; Jaime Bald; Torben Plesner; Joannes F M Jacobs; Niels W C J van de Donk; Philippe Moreau; Jordan M Schecter; Tahamtan Ahmadi; A Kate Sasser
Journal:  Clin Chem Lab Med       Date:  2016-06-01       Impact factor: 3.694

10.  The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.

Authors:  Marije B Overdijk; J H Marco Jansen; Maaike Nederend; Jeroen J Lammerts van Bueren; Richard W J Groen; Paul W H I Parren; Jeanette H W Leusen; Peter Boross
Journal:  J Immunol       Date:  2016-06-17       Impact factor: 5.422
View more
  20 in total

1.  Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice.

Authors:  Connie M Arthur; Jerry William L Allen; Hans Verkerke; Justin Yoo; Ryan P Jajosky; Kathryn Girard-Pierce; Satheesh Chonat; Patricia Zerra; Cheryl Maier; Jen Rha; Ross Fasano; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Blood Adv       Date:  2021-01-26

2.  Antibody-mediated immune suppression by antigen modulation is antigen-specific.

Authors:  Cheryl L Maier; Amanda Mener; Seema R Patel; Ryan P Jajosky; Ashley L Bennett; Connie M Arthur; Jeanne E Hendrickson; Sean R Stowell
Journal:  Blood Adv       Date:  2018-11-13

3.  Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice.

Authors:  Seema R Patel; Ashley Bennett; Kathryn Girard-Pierce; Cheryl L Maier; Satheesh Chonat; Connie M Arthur; Patricia E Zerra; Amanda Mener; Sean R Stowell
Journal:  Blood Adv       Date:  2018-01-23

4.  Antibody-mediated immunosuppression can result from RBC antigen loss independent of Fcγ receptors in mice.

Authors:  Amanda Mener; Seema R Patel; Connie M Arthur; Sean R Stowell
Journal:  Transfusion       Date:  2018-11-26       Impact factor: 3.157

5.  Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

Authors:  Jakub Krejcik; Kris A Frerichs; Inger S Nijhof; Berris van Kessel; Jeroen F van Velzen; Andries C Bloem; Marloes E C Broekmans; Sonja Zweegman; Johan van Meerloo; René J P Musters; Pino J Poddighe; Richard W J Groen; Christopher Chiu; Torben Plesner; Henk M Lokhorst; A Kate Sasser; Tuna Mutis; Niels W C J van de Donk
Journal:  Clin Cancer Res       Date:  2017-10-12       Impact factor: 12.531

Review 6.  Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion Reactions.

Authors:  Connie M Arthur; Satheesh Chonat; Ross Fasano; Marianne E M Yee; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Transfus Med Rev       Date:  2019-10-18

7.  Daratumumab Interference in Pretransfusion Testing Is Overcome by Addition of Daratumumab Fab Fragments to Patients' Plasma.

Authors:  Egon Werle; Josefin Ziebart; Eleonora Wasmund; Kristin Eske-Pogodda
Journal:  Transfus Med Hemother       Date:  2019-03-12       Impact factor: 3.747

8.  Examination of Whole-Cell Galectin Binding by Solid Phase and Flow Cytometric Analysis.

Authors:  Anne Leppänen; Connie M Arthur; Sean R Stowell; Richard D Cummings
Journal:  Methods Mol Biol       Date:  2022

9.  Evaluation of the Bactericidal Activity of Galectins.

Authors:  Nourine A Kamili; Anu Paul; Shang-Chuen Wu; Marcelo Dias-Baruffi; Richard D Cummings; Connie M Arthur; Sean R Stowell
Journal:  Methods Mol Biol       Date:  2022

Review 10.  Overcoming Drug Interference in Transfusion Testing: A Spotlight on Daratumumab.

Authors:  Marilyn T Nedumcheril; Robert A DeSimone; Sabrina E Racine-Brzostek; Ok Kyong Chaekal; Ljiljana V Vasovic
Journal:  J Blood Med       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.